Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13068622 | 0.74 | CHRM2 (0.36) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL3564666 | 0.65 | CCNB2 (0.31) | — | |
| SCHEMBL14777515 | 0.65 | CCNB2 (0.32) | — | |
| SCHEMBL17410397 | 0.63 | — | — | |
| SCHEMBL6108659 | 0.62 | — | — | |
| SCHEMBL20263723 | 0.62 | NPC1 (0.32) | — | |
| SCHEMBL1680716 | 0.61 | MEN1 (0.31) | — | |
| SCHEMBL20388652 | 0.61 | ALDH1A1 (0.33) | — | |
| SCHEMBL10561767 | 0.61 | HPGD (0.33) | — | |
| SCHEMBL20590031 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1860114-A | Benzoxazinone-derived sulfonamide compounds, process for their preparation and their use as pharmaceuticals | ESTEVE LABOR DR (ES) | 2006-11-08 | — | — | CN | claimed |
| US-7087590-B2 | 19-norbufalin derivatives, their preparation and pharmaceutical compositions containing them | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2006-08-08 | — | — | US | claimed |
| US-20030162701-A1 | 19-norbufalin derivatives, their preparation and pharmaceutical compositions containing them | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2003-08-28 | — | — | US | claimed |
| EP-1280816-A1 | 19-NORBUFALIN DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2003-02-05 | — | — | EP | claimed |
| WO-2001079256-A1 | 19-NORBUFALIN DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2001-10-25 | — | — | WO | claimed |
| US-10426762-B2 | Inhibitors of hepatitis C virus polymerase | COCRYSTAL PHARMA, INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-20170273962-A1 | Inhibitors of Hepatitis C Virus Polymerase | COCRYSTAL PHARMA, INC. | 2017-09-28 | — | — | US | disclosed |
| CN-106470986-A | Cyclohexene 1 yl pyridines 2 base 1H pyrazoles 4 formic acid derivates and its purposes as soluble guanylate cyclase activators | 诺华股份有限公司 | 2017-03-01 | — | — | CN | disclosed |
| US-9284303-B2 | Benzimidazole cannabinoid agonists bearing a substituted heterocyclic group | JANSSEN PHARMACEUTICA N.V. (BE) | 2016-03-15 | — | — | US | disclosed |
| US-20130324529-A1 | BENZIMIDAZOLE CANNABINOID AGONISTS BEARING A SUBSTITUTED HETEROCYCLIC GROUP | JANSSEN PHARMACEUTICA NV (BE) | 2013-12-05 | — | — | US | disclosed |
| US-8524757-B2 | Benzimidazole cannabinoid agonists bearing a substituted heterocyclic group | JANSSEN PHARMACEUTICA NV (BE) | 2013-09-03 | — | — | US | disclosed |
| US-20130217664-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2013-08-22 | — | — | US | disclosed |
| EP-1430042-A2 | BICYCLIC HETEROCYCLES AS RXR LIGANDS | SmithKline Beecham Corporation (US) | 2004-06-23 | — | — | EP | disclosed |
| WO-2003076440-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS CALCITONIN AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-09-18 | — | — | WO | disclosed |
| US-20030162701-A1 | 19-norbufalin derivatives, their preparation and pharmaceutical compositions containing them | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2003-08-28 | — | — | US | disclosed |
| WO-2003027090-A2 | BICYCLIC HETEROCYCLES AS RXR LIGANDS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
| EP-1280816-A1 | 19-NORBUFALIN DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2003-02-05 | — | — | EP | disclosed |
| WO-2001079256-A1 | 19-NORBUFALIN DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2001-10-25 | — | — | WO | disclosed |
| EP-0975633-A1 | 5,6,7-TRISUBSTITUTED-4-AMINOPYRIDOL 2,3-D]PYRIMIDINE COMPOUNDS | Abbott Laboratories (US) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998046604-A1 | 5,6,7-TRISUBSTITUTED-4-AMINOPYRIDOL[2,3-D]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 1998-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162701-A1 | 19-norbufalin derivatives, their preparation and pharmaceutical compositions containing them | ATP6V1B2, ATP6V1B1, ATP1A2 | CHRM2 4038/4885CHRM4 4424/4885CHRM5 4590/4885 |
| US-10426762-B2 | Inhibitors of hepatitis C virus polymerase | POLR2E, POLR2H, GTF3C3 | CHRM2 3992/4885CHRM4 4410/4885CHRM5 4121/4885 |
| US-20130324529-A1 | BENZIMIDAZOLE CANNABINOID AGONISTS BEARING A SUBSTITUTED HETEROCYCLIC GROUP | CNR1, CNR2, GPR18 | CHRM2 667/4885CHRM4 340/4885CHRM5 490/4885 |
| US-20130217664-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | JAK1, IL6, JAK3 | CHRM2 361/4885CHRM4 1463/4885CHRM5 1256/4885 |
| US-20170273962-A1 | Inhibitors of Hepatitis C Virus Polymerase | POLR2E, POLR2H, GTF3C3 | CHRM2 3992/4885CHRM4 4410/4885CHRM5 4121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.